Scientists exploit leaks in blood brain barrier to treat glioblastoma

November 6, 2017, Cancer Research UK

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma, suggest results presented at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool, today (Monday).

The Cancer Research UK-funded OPARATIC trial, which was managed by the charity's Centre for Drug Development, tested whether the ovarian cancer drug olaparib could reach glioblastoma, a type of tumour which is very difficult to treat. And early results show it successfully reaches at high enough levels for treatment.

The successful delivery of this drug is an important step as many others have failed to reach the tumour.

The study recruited 48 patients with glioblastoma which had returned after initial treatment. The majority of patients were then given olaparib in combination with the chemotherapy drug temozolomide.

Scientists looked at tumour samples and found that the drug penetrates the core of the as well as the surrounding areas which contain smaller numbers of cancerous cells. Cancer cells in these regions cannot be removed by surgery so reaching them with drugs is crucial.

The researchers also identified a way to safely combine both drugs by giving olaparib intermittently, minimising dangerous side effects.

Olaparib is a PARP inhibitor, which is already used to treat certain ovarian cancer patients and prevents damaged from repairing themselves after chemotherapy or radiotherapy.

The OPARATIC trial has paved the way for two additional clinical trials – PARADIGM and PARADIGM-2 – testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.

Professor Anthony Chalmers, lead researcher and Chair of Clinical Oncology at the University of Glasgow, said: "Brain tumours are stubbornly difficult to treat and one of the main reasons for this is the blood brain barrier, a natural filter that blocks the passage of drugs.

"But these results suggest that olaparib is able to leak through because this barrier is disrupted in glioblastoma. By showing that this reaches brain tumours, we are in a much stronger position to use it to make current treatments more effective."

Dr Nigel Blackburn, Cancer Research UK's director of , said: "While overall survival for cancer is improving, survival for brain tumours is still very low and the is a significant pharmacological obstacle.

"Experimental trials like this, which test new ways to reach these hard to treat tumours, are crucially important if we are to see more patients survive their cancer."

Professor Susan Short, member of NCRI's Radiotherapy Research Working Group, said: "We're just beginning to realise the full potential of PARP inhibitors to tackle many different types of , so it's exciting to see that olaparib could potentially be used to treat glioblastoma in combination with chemotherapy and radiotherapy.

"These results are a huge step forwards in developing better treatments for patients with brain tumours, which claim too many lives every year."

Explore further: Pancreatic cancer trial to make tumours more sensitive to treatment

Related Stories

Pancreatic cancer trial to make tumours more sensitive to treatment

August 30, 2016
Cancer Research UK (CRUK) launches a first-of-its-kind pancreatic cancer clinical trial to make cancer cells more responsive to chemotherapy and radiotherapy, with University of Glasgow researcher Professor Jeff Evans as ...

Potential treatment for brain cancer as drug shrinks tumours

August 14, 2017
An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, a common form of childhood brain tumour.

Brain tumors share common tricks to survive

October 25, 2017
Different types of brain tumours may use strikingly similar approaches to generate and use energy to survive in the brain, according to a new study published in PLOS ONE today.

Revamped drug may overcome resistance in brain tumours

January 14, 2015
Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults, according to research published in Molecular Cancer Therapeutics.

BRCA-targeting drugs could treat prostate cancer, leading expert says

November 5, 2014
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.

Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour

June 3, 2016
GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent.

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.